BNC210
This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (May 2014) (Learn how and when to remove this template message) |
Clinical data | |
---|---|
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
|
|
PubChem (CID) | 7019084 |
ChemSpider | 5382052 |
Chemical and physical data | |
Formula | C17H23N3O3 |
Molar mass | 317.39 g·mol−1 |
3D model (Jmol) | Interactive image |
|
|
|
BNC210 (also known as IW-4123 during its time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug that acts via negative allosteric modulation of the α7-nicotinic acetylcholine receptor,[1] by Bionomics Limited. It demonstrates clinically significant anxiety reduction in both animal models and in Phase I trials.[2]
It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models.[3]
Phase I trials have shown no serious side effects.
Bionomics previously licensed it to Ironwood Pharmaceuticals in January 2012, where it was known as IW-2143. In December 2012, IW-2143 begun undergoing phase I clinical trials in the United States,[4] but in November 2014, was released back to Bionomics in a mutual agreement.[5] Bionomics will now continue development and clinical testing, with Ironwood receiving a royalty for their work done.
As of April 2015, BNC210 is in phase II clinical trials.[6]
See also[edit]
References[edit]
- ^ http://www.bionomics.com.au/upload/investors/asx-announcements/4736/ASX695%20%20BNC210%20Phase%201b%20initiation.pdf
- ^ "Bionomics - Pipeline". Retrieved 2010-11-09.
Bionomics has discovered a novel compound, BNC210, that offers dramatic competitive advantages over existing treatments
- ^ O'Connor, S.; Andriambeloson, E.; Huyard, B.; Wagner, S.; Sleebs, B.; Quasi, N.; Bui, C.; Street, I. "BNC210: A Novel Compound with Potent Anxiolytic Activity" (PDF). Bionomics Limited. Retrieved 2010-11-09.
By applying a targeted medicinal chemistry strategy beginning from a compound cited in the literature, Bionomics has developed BNC210
- ^ http://investor.ironwoodpharma.com/releasedetail.cfm?ReleaseID=733540
- ^ http://www.biotechdaily.com.au/media/backissues/2014/11%20Nov/BD%20Biotech%20Daily%20Nov%2011.pdf
- ^ Bionomics Limited. "www.prnewswire.com" (HTML). PRNewswire. Retrieved 2015-06-10.
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |